Cargando…

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance

Immune checkpoint blockades (ICBs) have revolutionized cancer treatment. Recent studies have revealed a subset of triple-negative breast cancer (TNBC) to be considered as an immunogenic breast cancer subtype. Characteristics of TNBC, such as higher mutation rates and number of tumor-infiltrating imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyungjoo, Choi, Je-Min, Lee, Kyung-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138553/ https://www.ncbi.nlm.nih.gov/pubmed/35625867 http://dx.doi.org/10.3390/biomedicines10051130

Ejemplares similares

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
por: Xu, Chao, et al.
Publicado: (2023)

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
por: Palakurthi, Bhavana, et al.
Publicado: (2023)

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
por: Uchimiak, Katarzyna, et al.
Publicado: (2022)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer
por: Ren, Xijiao, et al.
Publicado: (2023)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer
por: Son, Seogho, et al.
Publicado: (2023)

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
por: Crosby, Erika J., et al.
Publicado: (2018)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
por: Drakes, Maureen L., et al.
Publicado: (2020)

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
por: Sun, Kai, et al.
Publicado: (2022)

ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer
por: Wang, Guanpeng, et al.
Publicado: (2022)

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021)

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
por: Miljanic, Mihailo, et al.
Publicado: (2020)

Checkpoint blockade in the treatment of breast cancer: current status and future directions
por: Wein, Lironne, et al.
Publicado: (2018)

Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model
por: Song, Haa-Na, et al.
Publicado: (2021)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors
por: Chen, Xin‐Yu, et al.
Publicado: (2023)

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
por: Kleef, Ralf, et al.
Publicado: (2018)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()
por: Brown, Lauren C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1u4mgseni9trip5vulrcueuj5m